6c3fd2dd__Trials_Monthly___October_2013__Description
[NCI Designation] NCT01779791 [Disease Site] Lymphoma [Description] 
An Open-Label, Multicenter, Single-Arm, Phase II Study of PCI-32765 (Ibrutinib) in Subjects with Refractory Follicular Lymphoma
Seattle Cancer Care Alliance | Clinical Trials Monthly - October 2013
Description